Alkemi

Alkemi is listed as a small business research supplier in the Scientist.com network, with 1 site in 1 country.

Search companies, drugs, suppliers and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Sites 1

Countries 1

Type of company: Small business

Clinical Consulting

Study Budgeting Consulting Request for Consulting Services

Data Science/Bioinformatics

RWE/HEOR Data Science and Modeling A process that helps make sense of your clinical data
RWE/HEOR Drug/Therapy Discontinuation Analysis An analysis to understand patient behavior. Are the drugs taken on time, do the patients discontinue use, and if so how long after starting, etc.
RWE/HEOR Market Analysis A process to understand how a drug is performing in the market and possible opportunities in the market

HEOR

Burden of Illness/Disease Strategy and study related to assessing the impact (economic, non-economic) of disease on health outcomes in a country, region, community, patient, or health system.
Clinical Outcome Assessments (Non-Patient Reported) Measure a patient's symptoms, mental state and level of disease condition-related impact on daily life.
Clinical Outcomes Measures patient's symptoms, mental, or physical effects of a disease or condition on how the patient functions, recorded by practitioner, provider, or instrument (not by patient).
Comparative Effectiveness The generation and synthesis of evidence that compares the benefits and harms of alternative methods to prevent, diagnose, treat, and monitor a clinical condition or to improve the delivery of care.
Cost Benefit Analysis Economic evaluation in which costs and benefits (outcomes) are expressed in monetary units, to determine if the benefits of an intervention outweigh the costs.
Cost Effectiveness Analysis Compare alternative treatments that lead to similar health outcomes.

Show all 14 in HEOR 8 more

Decision Analytic Modeling Assess effects, costs and economic outcomes of treatment. These include cost-effectiveness models and budget impact models.
Health Economics and Outcomes Research (HEOR) Evaluate data collected during drug development to maximize the value of a therapeutic product.
HEOR Adherence Studies Strategy or study that assess extent to which patients or subjects follow recommendations for prescribed intervention; may include compliance assessment, as well as reasons related to actual or potential non-adherence.
Patient Reported Outcomes (PRO) Assessment of health outcomes directly reported by the patient who experienced it, without interpretation of the patient's response by a clinician.
Patient Treatment Patterns Assessment of treatment processes and patterns within clinical practice.
Resource Utilization Descriptive and/or analytical review of a treatment that investigate the marketing, distribution, prescription, and use of drugs in populations. Endpoints to be assessed are the medical, social, and economic outcomes.
Systematic Literature Review Summarizes the results of research (that meet pre-defined eligibility criteria for inclusion) and provides a high level of evidence on the outcomes assessed.
Therapy Switch Insight into the reasoning of patients switching treatments and the outcomes of the switch.

Market Access

Academy of Managed Care Pharmacy (AMCP) Dossier Summary document that presents clinical, economic, and humanistic value of an intervention and associated disease state with the supporting evidence, formulated from the perspective of a particular stakeholder...
Budget Impact Models A budget impact model (BIM) is a health economic tool used by decision-makers (such as hospitals, health boards, and payers) to estimate the financial consequences of adopting a new healthcare intervention, like a new...
Communication & Advertisement Distribution of a range of materials, through various communication channels, to highlight a message containing scientific-related topics
Emerging Market Opportunities Analyze risks and opportunities in new markets and ensure patients have timely and continued access to new treatments.
Formulary & Reimbursement Strategy Develop strategy and narrative to gain formulary access on insurance plans.
Health Technology Assessment (HTA) Preparation/Strategy Dossier Development Perform evidence preparation and/or create strategies for the systematic evaluation of the properties, effects, and/or impacts of health care technology.

Show all 15 in Market Access 9 more

Health Technology Assessment Submission (HTA Submission) Analyze the medical, social, ethical, humanistic, and economic considerations of a drug, medical device, or clinical procedures. Submissions are sent to regulatory agencies with different requirements that govern...
Life Science Reports Life Science reports
Market Access - HTA Landscape Assessment Conduct a HTA landscape assessment to evaluate the direct and indirect impact of health technology on a specific region.
Marketing and Commercialization Identify, promote and prove the value of a particular drug to key stakeholders.
Pharmaceutical Reports Pharmaceutical Reports
Pricing Strategy Develop value story tailored to a payer audience that will determine the appropriate price for treatment.
Study Start Up Consulting Request for RWE/HEOR/Market Access Study Start Up Consulting
Value Based Agreements or Outcomes-Based Contracts Collaborate with payer or provider to develop a reimbursement plan outside of the traditional fixed cost-per-unit that ties reimbursement or price to actual health outcomes.
Value Dossiers Development Summary document that presents clinical, economic, and humanistic value of an intervention and associated disease state with the supporting evidence, formulated from the perspective of a particular stakeholder...

Show all 40 services 24 more

Medical Communications

HEOR/Value Publications Writing and submission of manuscripts and abstracts focusing on Health Economics and Outcomes Research (HEOR) data, which demonstrate the economic and value proposition of a therapy.

Primary Market Research

Payer and HTA Expectations Research Engages payers and HTA bodies to uncover evidence needs, pricing thresholds, and access drivers. Informs clinical and economic evidence generation planning.

Real World Evidence & Data

RWE/HEOR Data Analysis Analysis that helps you make sense of your RWE/HEOR data
Secondary Real World Evidence Analyze clinical trial data.

Regulatory Affairs

AMP Dossier Clinical Trial Dossier and/or United States Market Access Dossier
Life Cycle Management Plan and strategy of the data collection and information throughout the different phases of product development (portfolio assessment, pre-clinical trials, clinical trials, pre-authorization, post-authorization, and RWE)
Risk Benefit Assessment Determine ratio of treatment risk to the potential benefits.

Website: www.alkemihealth.com

United States Green Cove Springs 1 site

Woman-owned

US small-business federal-contractor designation, self-certified in the U.S. federal System for Award Management (SAM.gov). Coverage is limited to matched U.S. small-business suppliers, so an absent designation is not evidence of its absence.

Work with Alkemi on Scientist.com

For prices, more details, or to contact Alkemi, visit Scientist.com.

View on Scientist.com